Diversity versus Focus in Choosing Targets and Therapeutic Areas
作者： D.A. Giegel , A.J. Lewis , P. Worland
DOI: 10.1016/B0-08-045044-X/00061-4
关键词:
摘要: The pharmaceutical industry is confronted with several important challenges today, including the need to sustain their pipelines and offset patent expirations inevitable generic competition. biotechnology continues deliver innovative drugs as it moves from being a technology-driven product-driven industry. Not unexpectedly, has aggressively partnered companies fill pipeline gaps. This chapter briefly covers how some of current have been built, they matured. There are number issues that currently confront drug discovery whole, whether company involved major or just getting started. These discussed, proposal made for building scratch today's funding situation.
elsevier.com
sci-hub.se 参考文章(38)
Katharine E. Winkler, Killing the messenger Nature Reviews Drug Discovery. ,vol. 3, pp. 823- 824 ,(2004) , 10.1038/NRD1527
Innovation and greater probability of success in drug discovery and development -- from target to biomarkers. Current Opinion in Biotechnology. ,vol. 16, pp. 644- 646 ,(2005) , 10.1016/J.COPBIO.2005.10.014
David Bailey, Edward Zanders, Philip Dean, The end of the beginning for genomic medicine Nature Biotechnology. ,vol. 19, pp. 207- 209 ,(2001) , 10.1038/85627
Bruce Booth, Rodney Zemmel, Prospects for productivity. Nature Reviews Drug Discovery. ,vol. 3, pp. 451- 456 ,(2004) , 10.1038/NRD1384
Philip Ma, Rodney Zemmel, Value of novelty Nature Reviews Drug Discovery. ,vol. 1, pp. 571- 572 ,(2002) , 10.1038/NRD884
Leland J. Gershell, Joshua H. Atkins, A brief history of novel drug discovery technologies Nature Reviews Drug Discovery. ,vol. 2, pp. 321- 327 ,(2003) , 10.1038/NRD1064
Andrew Fire, SiQun Xu, Mary K. Montgomery, Steven A. Kostas, Samuel E. Driver, Craig C. Mello, Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans Nature. ,vol. 391, pp. 806- 811 ,(1998) , 10.1038/35888
Kyle Jensen, Fiona Murray, Intellectual Property Landscape of the Human Genome Science. ,vol. 310, pp. 239- 240 ,(2005) , 10.1126/SCIENCE.1120014
Ismail Kola, John Landis, Can the pharmaceutical industry reduce attrition rates? Nature Reviews Drug Discovery. ,vol. 3, pp. 711- 716 ,(2004) , 10.1038/NRD1470
Paolo Preziosi, Science, pharmacoeconomics and ethics in drug R&D: a sustainable future scenario? Nature Reviews Drug Discovery. ,vol. 3, pp. 521- 526 ,(2004) , 10.1038/NRD1418